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ABSTRACT 
Parasite proteins containing repeats are essential invasion ligands, important for their ability to 
evade the host immune system and to induce immunosuppression. Here, the intrinsic 
suppressive potential of repetitive structures within parasite proteins was exploited to induce 
immunomodulation in order to establish self-tolerance in an animal model of autoimmune 
neurological disease. 
We tested the tolerogenic potential of fusion proteins containing repeat sequences of parasites 
linked to self-antigens. The fusion constructs consist of a recombinant protein containing repeat 
sequences derived from the S-antigen protein (SAg) of Plasmodium falciparum linked to a CD4 
T cell epitope of myelin. They were tested for their efficacy to control the development of 
experimental autoimmune encephalomyelitis (EAE), In addition, we used the DO11.10 
transgenic mouse model to study the immune mechanisms involved in tolerance induced by 
SAg fusion proteins. 
We found that repeated sequences of P. falciparum SAg protein linked to self-epitopes 
markedly protected mice from EAE. These fusion constructs were powerful tolerizing agents not 
only in a preventive setting but also in the treatment of ongoing disease. The tolerogenic effect 
was shown to be antigen-specific and strongly dependent on the physical linkage of the T cell 
epitope to the parasite structure and on the action of anti-inflammatory cytokines like IL-10 and 
TGF-β. Other mechanisms include down-regulation of TNF-α accompanied by increased 
numbers of FoxP3+ cells. This study describes the use of repetitive structures from parasites 
linked to defined T cell epitopes as an effective method to induce antigen-specific tolerance with 
potential applicability for the treatment and prevention of autoimmune diseases.   
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1. Introduction 
Autoimmune disorders are the result of the breakdown of central and peripheral immune 
tolerance. The onset and progression of autoimmune diseases involve a complex mixture of 
endogenous and exogenous signals and predisposing factors that result in pathogenic 
inflammatory reactions mediated by auto-reactive cells (Rashedi et al., 2007). Current first 
line treatments for autoimmune neurological diseases like multiple sclerosis comprise 
disease-modifying drugs that moderately control exacerbations of disease and are, however, 
associated with generalized depression of the immune system. 
The main goal of immunotherapy is to target specifically autoreactive T cells while 
maintaining the immune system’s ability to fight foreign antigens avoiding generalized 
immunosuppression. Immunotherapy aimed to reestablish antigen-specific self-tolerance 
represents a promising strategy to modulate autoimmunity with potential applicability in 
translational research. Different methods, such as the application of high or low doses of a 
specific antigen and defined routes of administration are critical factors that determine the 
induction of immune tolerance. The doses and concentration of the antigen are often directly 
correlated with the generation of active and cell-dependent regulatory mechanisms (Turley 
and Miller, 2010) or with the induction of anergy (Bitar and Whitacre, 1988) or even deletion 
of antigen-specific T cells (Critchfield et al., 1994; Liblau et al., 1996; Apostolou and von 
Boehmer, 2004; Judkowski et al., 2004). Likewise, immunological tolerance achieved by oral 
(Higgins and Weiner, 1988; Weiner, 2000; Weiner et al., 2011) and intranasal (Anderton et 
al., 1998; Fossati-Jimack et al., 2015) delivery of autoantigens has shown to be mediated by 
active suppressor mechanisms such as anti-inflammatory cytokines and regulatory cells 
(Chen et al., 1995; Weiner et al., 2011). 
Recently, the use of carriers has shown to improve the stability, half-life and bioavailability of 
soluble peptides, increasing the efficacy of tolerogenic peptide vaccination by promoting the 
induction of antigen-specific T regulatory cells (Tregs) (Quintana, 2013; Gupta et al., 2015). 
Other recent approaches for the induction of specific immune tolerance include the use of 
synthetic nanoparticles containing specific proteins in combination with immunosuppressive 
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drugs (Maldonado et al., 2014), stem cell transplantation (Coleman and Steptoe, 2012) and 
gene transfer (Sack et al., 2014).   
We have shown previously that repetitive T cell self-epitopes are effective in the prevention 
and treatment of ongoing experimental autoimmune encephalomyelitis (EAE) (Falk et al., 
2000b; Puentes et al., 2013). This protection was shown to be antigen-specific and mediated 
by the induction of active suppression involving the action of anti-inflammatory cytokines like 
IL-10 and TGF-β. Multimerized antigens, initially thought to increase antigenicity by 
crosslinking MHC class II complexes on the surface of antigen presenting cells (APCs) and 
thereby leading to an enhanced T cell activation, have shown to suppress the clinical 
symptoms in experimental animal models of human autoimmune disease, like multiple 
sclerosis, autoimmune neuritis and type I diabetes (Falk et al., 2000b; Stienekemeier et al., 
2001; Piaggio et al., 2007; Puentes et al., 2013).  
Despite the abundance of natural repetitive regions in eukaryotic proteins, their function and 
structure are barely known (Huntley and Golding, 2004). More characterized are the 
repetitive structures present on the surface of parasites and the frequency and extent of this 
phenomenon in the parasite taxa suggests that it represents a special feature. It is suggested 
that natural selection of repeat-arrays in malaria parasites has been exerted as a mechanism 
of immune evasion (Hughes, 2004). In particular, intracellular parasites have a higher 
content of repetitive sequences (Bartholomeu et al., 2014) that play important roles such as 
cell adhesion, invasion and suppression to evade the host immune response (Mendes et al., 
2013).  
Recently, the significance of the suppression induced by several protozoan parasitic 
infections has been correlated with the outcome of autoimmune diseases, following 
concomitant infections. There is ample evidence that parasite infections can ameliorate the 
course of autoimmune diseases (Gibbon et al., 1997; Mattsson et al., 2000). For example, 
Plasmodium infection has shown to interfere with the EAE autoimmune response through the 
activation of Tregs (Farias et al., 2011). Similarly, infections with Trypanosoma can confer 
protection against autoimmunity in arthritis models (De Trez et al., 2015) and markedly 
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suppress the clinical course of experimental EAE, likely due to a modulatory effect of IL-10 
on Th1 expansion (Tadokoro et al., 2004). Moreover, certain parasites have been found to 
have the ability to skew the host’s response towards a Th2 phenotype, characterized by 
increased expression of IL-4, IL-5 and IL-13 (Mohrs et al., 2005). A similar phenomenon is 
observed in allergies, where helminth infections induce a regulatory CD4+CD25+FoxP3+ T 
cell population able to suppress allergic responses (Wilson et al., 2005).  
In the present study, fusion constructs composed of a recombinant protein containing repeat 
sequences from the S-Antigen of P. falciparum linked to T cell epitopes, were evaluated in 
the autoimmune EAE model for the ability of inducing tolerance. We chose the SAg protein 
as it represents a striking model of tandem repeats of amino acid sequences covering nearly 
two thirds of the parasite protein secreted in large amounts during the erythrocyte stage and 
it is well known to function as a target for the host immune system (Saint et al., 1987). 
Administration of a single dose of these repetitive structures linked to a CD4+ T cell epitope 
of myelin was sufficient to markedly inhibit the development of EAE. Some of the 
mechanisms involved in the protective effect induced by the constructs include the 
production of regulatory cytokines like IL-10 and TGF-β. Tolerance induction seems to be 
also associated with increased numbers of FoxP3 cells and down-regulation of Th1 
response. 
Results from this study suggest an immunomodulatory role of parasite repeat sequences 
anchored to self-antigens, which may have applications to vaccine design and treatment of 
human autoimmune diseases. 
2. Materials and Methods 
2.1 Ethics Statement 
The animals were maintained and handled according to the Directive 86/609/EEC of the 
European Community Council and to the institutional, state and federal guidelines. All animal 
protocols were approved by the ethics committee of the Landesamt für Gesundheit und 
Soziales (LAGeSo, Berlin, Germany) with registration numbers G0140-06 and G0331-08. 
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Animals were housed under standard conditions of 12-hour light/dark cycle and given access 
to food and water ad libitum. During periods of active paralysis, animals were provided gel 
pack and/or moistened food on the cage floor. Animals were sacrificed, by carbon dioxide 
overdose, when they met endpoint criteria or at study termination. 
2.2 Animals 
Mice were housed in the animal facility of the Max Delbrück Center under specific pathogen 
free conditions and handled in accordance with the institutional guidelines. Female C57BL/6 
(H-2b), SJL/J (H-2s) or JHT-/- (B6.129P2-Igh-Jtm1Cgn/J) mice (Gu et al., 1993), 10 to 12 
weeks old were used for EAE studies. SJL/J mice were purchased from Taconic 
Laboratories. C57BL/6 and Balb/c mice were purchased from Charles River Laboratories. 
DO11.10 (H-2d) and OTII (H-2b) transgenic mice were bred at the animal facility of the 
Deutsches Rheuma-Forschungszentrum (DRFZ) under SPF conditions (Bundesinstitut für 
Risikobewertung, Berlin). DO11.10 and OTII mice carry the MHC class II restricted 
rearranged T cell receptor transgene reactive to OVA323-339. JHT-/- mice were kindly provided 
by Dr. Simon Fillatreau (DRFZ, Berlin). These mice are homozygous for the Igh-Jtm1Cgn 
targeted mutation and fail to produce functional B-cells as they lack the gene for the heavy 
chain joining region.  
2.3 Peptides and fusion proteins 
Proteolipid protein derived PLP139-151 (C140S)(HSLGKWLGHPDKF) later referred as PLP139-
151, myelin oligodendrocyte glycoprotein MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) and 
ovalbumin OVA323-339 (ISQAVHAAHAEINEAGR) peptides (Research Genetics EMC, 
Tübingen, Germany) were synthesized by standard solid phase F-moc chemistry. All 
peptides were purified on a C4 -HPLC column (Vydac). 
Fusion proteins containing repetitive sequences of the S-antigen (SAg) of Plasmodium 
falciparum were designed as follows: 24 repeats of a 8-mer unit derived from the NF7 isolate 
(A(L/R)KSDEAE) were linked by a S3 spacer to the N-terminus of the respective CD4+ T cell 
epitopes: MOG38-51 (SAg-MOG38-51), PLP139-151 (C140S) (SAg-PLP139-151) and OVA323-339 
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(SAg-OVA323-339). Since the natural units contained either L or R in their repeats, building 
blocks with alternating amino acids were used in tandem repeats.  The generation and 
production was carried out by recombinant techniques in E. coli as described previously 
(Rotzschke et al., 1997). The constructs were isolated using a His-tag located at the C-
terminal site of the construct and purified by RP-HPLC to remove endotoxins. Endotoxin 
levels were determined using the limulus test (Charles River Laboratories). 
2.4 Induction of EAE and therapeutic effect of S-antigen fusion proteins  
EAE induction was performed as previously described (Puentes et al., 2013). Briefly, female 
SJL/J and C57BL/6 mice were immunized by subcutaneous injection on the dorsal region 
with 50 µg of PLP139-151 (C140S) or 50 µg of MOG35-55 peptide respectively. Peptides were 
emulsified in incomplete Freund's adjuvant (Sigma), containing 400 µg of Mycobacterium 
tuberculosis H37Ra (Difco, Detroit, USA). One day after immunization, 200 ng and 500 ng of 
Pertussis toxin (List Biological Laboratories, Inc UK) were administered intravenously to 
SJL/J and C57BL/6 mice respectively. Mice were scored daily for clinical signs of disease 
according to the following scale: 0, no clinical sign; 1, limp tail; 2, limp tail, impaired righting 
reflex, and paresis of one limb; 3, hind limb paralysis; 4, hind limb and forelimb paralysis; 5, 
moribund.  
The therapeutic effect of SAg fusion proteins was examined before and after disease 
induction. Concentration, dosing frequency and route of administration were based on our 
previous studies using repetitive self-peptides (oligomerized peptides), which showed that a 
single intravenous treatment with a low dosage of oligomers induced protective effect on 
experimental models of autoimmune diseases (Falk et al., 2000b; Stienekemeier et al., 2001; 
Puentes et al., 2013). SAg fusion proteins applied on the range of the peptide-concentration 
used to induce disease (dosages between 50 and 70 g), were shown to be safe and 
effective. For vaccination experiments, 7 days before induction of disease, SJL/J and 
C57BL/6 mice received intravenously 50 µg SAg-PLP139-151 or 70 µg SAg-MOG38-51 
respectively. In a therapeutic setting, mice were treated on day 7 after EAE induction (before 
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onset). Other group of mice was treated after the appearance of the first clinical signs of 
disease with the same amount of SAg-constructs as stated above. The effect of SAg-MOG 
constructs in the suppression of EAE was tested in B cell deficient JHT mice. EAE was 
induced in JHT-/- and JHT+/- mice by immunization with MOG35-55 peptide and further treated 
with SAg-MOG fusion protein as described above. 
2.5 In vitro T cell proliferation assay 
T cell proliferation assays with primary lymph node cells (LNC) were performed in 96-well 
round-bottom plates. Briefly, LNC were harvested from DO11.10 mice and after erythrocytes 
lysis, 5x105 cells/well were cultured in DMEM/10% FCS (Invitrogen- Karlsruhe, Germany) 
with titrated amounts of OVA323-339 peptide or SAg-OVA323-339. After 72 hours incubation, 
(3H)Thymidine (0,65 µCi/ well) (Amersham, Freiburg Germany) was added and 16 hours later 
the assay was harvested and counted in a Microplate Counter (Wallac 1420 Victor3TM-
Turku, Finland). Specific proliferation is indicated as (3H)Thymidine incorporation as counts 
per minute (cpm). 
2.6 Induction of delayed type hypersensitivity reaction (DTH) 
The effect of SAg fusion proteins on the modulation of inflammatory response was examined 
in a DTH assay. For the induction of an OVA-specific DTH reaction OVA323-339 -specific T 
cells were isolated from DO11.10 mice and 3x106 CD4+ T cells were adoptively transferred 
intravenously into Balb/c recipient mice. One day later, mice were tolerized by intravenous 
administration of 5 µg free OVA323-339, 60 µg SAg-OVA323-339 (equimolar amounts, based on 
OVA-peptide amount) or phosphate-buffered saline (PBS) as a control. OVA-specific Th1 
cells were generated in vitro by antigen-specific activation of naive CD4+ T cells from 
DO11.10 (Balb/c background) as previously described (Siegmund et al., 2005). Briefly, T 
cells from DO11.10 mice were cultured for 6 days in the presence of APCs, 1 µg/ml OVA 
peptide under Th1 polarizing conditions (5 ng/ml recombinant IFN-γ, 20 ng/ml recombinant 
IL-12 and 5 µg/ml αIL-4). This protocol results in the generation of an effector cell population 
containing 50 to 80% cells producing IFN-γ and less than 1% producing IL-4. A total of 5x105 
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OVA-specific CD4+ Th1 cells were adoptively transferred into treated mice on day 7. 24 
hours later, 250 ng of OVA323-339 peptide in 5 µl of Incomplete Freund’s adjuvant (IFA, 
Sigma) were injected subcutaneously into the left footpad. PBS/IFA was injected into the 
right footpad as a control. DTH reaction was measured on the following 8 days by 
determining footpad swelling using an Oditest micrometergauge (Kroeplin Längen-
messtechnik, Schlüchtern, Germany). Footpad swelling relative to day zero was plotted and 
further analyzed.  
2.7 In vivo neutralization of cytokines 
For in vivo neutralization of cytokines, EAE induced mice were treated with SAg fusion 
proteins and received 0.5 mg of anti-cytokine antibodies administered intraperitoneally on 
day 7, 9 and 11 after induction of disease. The effect of cytokine blockade on the clinical 
course of EAE was monitored daily. The following monoclonal antibodies were used: anti-IL-
10 receptor (αIL-10R) (clone 1B1.3a) (O'Farrell et al., 1998), anti-transforming growth factor 
beta (αTGF-β) (clone 1D11) (Dasch et al., 1989) and rat IgG1 isotype control (clone G1-113) 
(Sigma). αIL-10R and αTGF-β antibodies were produced at the Max Delbrück Center from 
hybridoma cell lines and purified on Protein G columns (Thermo Scientific-Pierce, Germany) 
followed by dialysis. The protein concentration was determined by Bradford test and 
endotoxin levels (<1 EU/mg protein) were detected using the limulus test (Charles River 
Laboratories). Hybridoma cell lines were kindly provided by Dr. Alexander Scheffold, 
Deutsches Rheuma-Forschungszentrum, (DRFZ, Berlin, Germany).  
2.8 In vivo antigen-specific CD4+ T cell response after SAg-OVA administration 
To compare the antigen-specific CD4+ T cell proliferation in response to free antigen and 
SAg fusion constructs, adoptive transfer experiments using TCR transgenic CD4+ T cells 
specific for the OVA323-339 peptide were performed. Briefly, CD4+ T cells were isolated from 
DO11.10 mice by negative selection using the CD4+ T cell isolation kit (Miltenyi Biotech, 
Bergisch-Gladbach, Germany) and depleted of CD90+ cells using MACS. Cell purification 
was assessed by FACS on a LSR II (BD Bioscience). 3x106 purified DO11.10 CD4+ T cells 
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were labeled according to manufacturer's recommendation with 5 µM carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE (CFSE); Molecular Probes, Eugene, OR) and 
adoptively transferred into sex-matched Balb/c recipient mice. One day later, animals 
received 5 µg OVA323-339 peptide or 60 µg SAg-OVA323-339 (equimolar amounts, based on 
OVA-peptide amount) administered intravenously. Antigen-specific proliferation was 
analyzed on day 6 after adoptive transfer. Briefly, lymph nodes and spleens were isolated 
and further processed to obtain single-cell suspensions. Erythrocytes lysis was performed 
and cells were stained with the indicated antibodies for further analysis by flow cytometry. 
Cells were gated on CD4+ KJ1.26+ T cells and the CFSE profile was further analyzed on the 
gated subset using CellQuest (BD Bioscience) or FlowJo software (Tree Star, San Carlos, 
CA).  
2.9 Analysis of FoxP3+ regulatory CD4+ T cells following SAg treatment 
To examine the role of FoxP3+ Tregs on the tolerogenic action of SAg constructs, 3x106 
DO11.10 CD4+ CFSE labeled T cells were intravenously transferred into Balb/c mice. One 
day later, mice received 5 µg of free OVA323-339, 60 µg of SAg-OVA (equimolar amounts, 
based on OVA-peptide amount) or 60 µg of SAg-MOG as control. Lymph node cells were 
isolated on day 6 and the frequency of Treg cells were determined by intracellular staining of 
FoxP3 using the mouse FoxP3 staining Kit (eBioscience). Cells were stained with CD25 
(clone PC61), CD4 and KJ1.26 antibodies (BD Pharmingen). The KJ1-26 antibody reacts 
with the DO11.10 clonotypic T cell receptor specific for OVA323-339. FoxP3 expression was 
analyzed on gated CD4+CD25+ KJ1.26+ CFSE+ T cells. 
2.10 Antigen-specific suppression of pro-inflammatory TNF-α following SAg 
treatment 
Antigen-specific TNF-α production by CD4+ T cells from animals that received SAg fusion 
constructs was compared with untreated mice after adoptive transfer experiments using OVA 
specific CD4+ T cells isolated from DO11.10 mice. 3x106 DO11.10 CD4+ T cells, labeled with 
CFSE, were transferred into Balb/c mice and one day after, they received intravenously 5 µg 
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of free OVA323-339, 60 µg SAg-OVA (equimolar amounts, based on OVA-peptide amount) or 
60 µg of SAg-MOG as a control. 7 days after, mice were primed subcutaneously with 
OVA323-339 peptide in complete Freund’s adjuvant (CFA) and sacrificed 6 days later. LNC 
were isolated and restimulated with 10 µg/ml OVA peptide and control peptide for 6 hours. 
Antigen-specific cytokine expression was analyzed on KJ1.26+ CD4+ T cells by intracellular 
staining of TNF-α. Frequencies of TNF-α+ cells were analyzed on gated CD4+ KJ1.26+ T 
cells.  
To measure the production of TNF-α in JHT mice, OTII (OVA323-339 specific) cells labeled 
with CFSE were transferred into OVA323-339 primed JHT+/- and JHT-/- mice and treated with 
SAg-OVA.  Lymph node cells were isolated from treated and untreated mice and activated 
for 6 hours with OVA323-339 peptide and α-CD28 (clone 37.51) (Gross et al., 1992) purified at 
the Max Delbruck Center. The hybridoma cell line was kindly provided by Dr. Alexander 
Scheffold, Deutsches Rheuma-Forschungszentrum, (DRFZ, Berlin, Germany). 5 g/ml 
Brefeldin A (Sigma) was added for the last 4 hours of stimulation for blocking cytokine 
secretion. Cells were stained for surface CD4 using α-CD4 (clone RM4-5) BD Pharmingen 
(San Diego, CA), followed by intracellular staining with αTNF-α (clone XT22), BD 
Pharmingen. For TNF-α detection in antigen-specific activated T cells, combined intracellular 
α-CD154 (clone MR1) (Miltenyi Biotech, Bergisch-Gladbach, Germany) and TNF-α staining 
was performed (Frentsch et al., 2005; Puentes et al., 2013). The frequency of CD154+TNF-
α+ double positive in OTII CD4+ T cells was determined and analyzed on a LSR II cytometer 
with a BD Bioscience FACSDivaTM software. 
2.11 Statistical analysis 
For comparison of clinical EAE scores, significance between groups was determined by 
nonparametric Mann-Whitney U test. Data represent the mean ±SEM ***P<0.001, **P<0.01, 
*P<0.05. P values *P<0.05 were considered significant. Calculations were made using 
Sigmaplot software (San Jose). 
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3. Results 
3.1 Parasite tandem repeats linked to single-encephalitogenic T cell epitopes 
are sufficient to protect mice from EAE 
Our previous studies have shown that repeat antigens consisting of linear copies of T cell 
epitopes are able to suppress the clinical disease in various autoimmune model systems 
(Rotzschke et al., 1997; Falk et al., 2000b; Falk et al., 2000a; Mack et al., 2001; 
Stienekemeier et al., 2001; Piaggio et al., 2007; Puentes et al., 2013). In the present study, 
we wanted to investigate the suppressive capacity of parasite derived repeat structures 
linked to encephalitogenic epitopes in an experimental mouse model of multiple sclerosis. 
New constructs consisting of repeat sequences derived from Plasmodium S-Antigen linked to 
single CD4+ T cell epitopes were designed and tested for their ability to induce suppression. 
PLP139-151 and MOG38-51 are encephalitogenic CD4+ T cell epitopes that induce EAE in 
SJL/J and C57BL/6 mice, respectively. A diagram of the construct consisting of 24 repeats of 
a 8mer unit (A(L/R)KSDEAE) linked to the N-terminus of different relevant CD4+ T cell 
epitopes: PLP139-151 (SAg-PLP), MOG38-51 (SAg-MOG) and OVA323-339 (SAg-OVA), is 
depicted in Fig. S1A. Successful purification of fusion proteins is shown in Fig. S1B.  
A single dose of SAg constructs was administered to EAE induced mice with three different 
regimes: 7 days prior disease induction, 7 days after EAE induction or therapeutically treated 
soon after disease onset. Fig. 1 shows that a single injection of the SAg fusion constructs in 
SJL/J mice inhibits significantly the paralysis associated with EAE. SAg-PLP139-151 
vaccinated mice developed very mild signs of EAE (maximal average clinical score of 
0.6±0.6) at the peak of the disease by day 19, in contrast to untreated animals with a 
maximum score of 2.4±0.4 (Fig. 1A). Moreover, administration of SAg-PLP constructs 7 days 
after the induction of EAE markedly protected mice from disease development. Treated 
animals showed only mild clinical signs of disease compared to the control group that was 
left untreated (Fig. 1B). Likewise, vaccination and treatment of C57BL/6 mice with SAg-
MOG38-51 clearly inhibited EAE onset compared to their control groups, which developed 
severe disease showing mean maximal scores of 2.4±0.2 and 2.8±0.2 respectively (Figs. 1C 
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and 1D). This clearly shows that treatment with the fusion protein containing the residues 
MOG38-55 is sufficient to effectively protect mice from EAE induced with MOG35-55. Parasite 
derived fusion proteins linked to CD4+ epitopes not only protected animals from autoimmune 
attack when administered in a preventive manner; in fact, they could also inhibit the evolution 
of disease when given after the onset of EAE (Fig. S2).  
3.2 Antigen-specific effect of SAg fusion proteins 
To demonstrate that the suppression induced by SAg constructs is antigen-specific, a fusion 
protein containing an unrelated epitope was included. For this purpose, SJL/J mice were 
treated with SAg-PLP or unrelated SAg-MOG. As depicted in Fig. 2, animals that received 
SAg-MOG developed severe disease (100% incidence) with a maximum clinical score of 
2.6±0.2, comparable to untreated mice (maximum score 2.4±0.4). In contrast, the clinical 
course of EAE in mice treated with SAg-PLP protein, was significantly diminished (maximum 
score 0.4±0.2). Similarly, SJL/J mice vaccinated with non-specific SAg-OVA constructs 
developed EAE similar to untreated mice in contrast to SAg-PLP vaccinated mice that were 
significantly protected against disease development (Fig. S3). These results clearly 
demonstrate the strong tolerogenic effect of the SAg fusion constructs, which is highly 
specific for the coupled T cell antigen. 
3.3 Tolerogenic effect requires physical linkage of parasite repetitive sequence 
to T cell epitope  
To demonstrate that the parasite derived component does not exhibit tolerogenic effects by 
itself, we performed experiments using free SAg and CD4+ T cell epitopes administered 
together but not physically linked. Mice were treated with equimolar amounts of free SAg 
repeat alone or in combination with free PLP peptide. Results show animals treated with 
SAg-PLP fusion constructs inhibited EAE development; they showed very mild signs of 
disease with a maximum clinical score of 0.4±0.2 compared to the control group (maximum 
clinical score of 2.4±0.4) (Fig. 3). Protection was completely abrogated when the individual 
components were administered together but not physically linked, reaching similar clinical 
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score as the untreated group (maximum score of 2.4±0.2). Similarly, in a preventing setting, 
vaccination with the SAg alone did not result in any significant suppressive effect, in contrast 
to the SAg fusion protein which inhibited the development of disease (Fig. S4). The results 
clearly show that the physical link between the T cell epitope and the repeat structure is 
essential for the effectiveness of the treatment. 
3.4 Analysis of the antigen-specific T cell response in vitro 
We evaluated the capacity of SAg fusion proteins to induce proliferation in comparison to 
free peptides. T cells purified from lymph nodes of naive DO11.10 mice expressing a 
transgenic α/β TCR specific for OVA323–339 peptide were stimulated with titrated amounts of 
fusion proteins (SAg-OVA) or free OVA peptide. OVA-specific T cells responded to 
stimulation with SAg-OVA fusion constructs though to a lesser extend compared to free OVA 
peptide. Higher concentration of SAg-OVA was required for T-cell activation compared to the 
peptide. In addition, non-related SAg-MOG did not induce any non-specific proliferation, 
ruling out any effect of the parasite-derived repeat unit (Fig. S5). The same results were 
obtained using LNC from OTII mice which also express an OVA323-339 specific T cell 
receptor on CD4+ cells but on the C57BL/6 background (data not shown).  
These results indicate that SAg fusion proteins can be efficiently presented to be recognized 
by naive transgenic T cells to induce proliferation. 
3.5 Analysis of the antigen-specific T cell response in vivo 
As the suppressive effect of SAg fusion constructs was evident in mouse models of 
autoimmune inflammatory disease, we wanted to further analyze the antigen-specific CD4+ T 
cell response using the OVA transgenic mouse model. Antigen-specific immunotherapy is 
often associated with an impairment of antigen-specific response (Melamed and Friedman, 
1993; Miller et al., 2007). To test the effect of SAg fusion proteins in the antigen-specific 
proliferative capacity, OVA323-339 specific CD4+ T cells from DO11.10 mice were labeled with 
CFSE and transferred into sex-matched Balb/c mice, which received equimolar amounts 
(based on OVA-peptide amount) of free OVA peptide or SAg-OVA fusion constructs. To 
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evaluate T cell response to the cognate peptide OVA323–339, lymph node cells were 
harvested on day 6 after transfer and antigen-specific proliferation was determined by CFSE 
dye dilution. The DO11.10 clonotypic KJ1.26 antibody was additionally used to stain OVA 
specific T cells (Haskins et al., 1983). Results indicate that OVA specific T cells readily 
proliferated in response to SAg-fusion protein as well as to free OVA peptide. Cells from 
SAg-OVA and free OVA treated mice underwent a similar number of divisions as shown in 
Fig. 4. Unrelated SAg-MOG used as a control, did not induce any proliferation (data not 
shown). This indicates that administration of SAg-OVA did not limit the response to the 
cognate antigen but induced a CD4+ T cell response highly specific for the coupled T cell 
epitope.  
3.6 SAg fusion proteins treatment increased the number of regulatory FoxP3+ 
CD4+ T cells 
To investigate the role of regulatory FoxP3+ CD4+ T cells in suppression mediated by SAg 
fusion proteins, we performed adoptive transfer experiments using CFSE labeled OVA323–339 
specific CD4+ T cells as previously described. LNC from animals that received OVA specific 
T cells and were treated with SAg-OVA or free OVA were analyzed for the expression of 
FoxP3+ in antigen-specific cells. We observed about 1.5 fold increase in the Treg 
frequencies in mice that received SAg-OVA (23-25% of KJ1.26+CD4+CD25+FoxP3+ T 
cells), compared to animals receiving free OVA peptide (14-19% of 
KJ1.26+CD4+CD25+FoxP3+ T cells) (Fig. 5). Proliferation of FoxP3 cells was specific for the 
cognate antigen as cells from mice that received unspecific SAg-MOG did not proliferate,  
showing 3-7% of KJ1.26+CD4+FoxP3+ T cells which reflects normal frequencies of 
regulatory T cells in the mature CD4+CD25+ T cell subpopulation (Sakaguchi, 2004). This 
also indicates that the parasite-derived repeat unit itself neither induces nor expands 
regulatory T cells (Treg) in this setting. Together these results show that SAg fusion proteins 
induced increased proliferative response of regulatory T cells.  
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3.7 Tolerogenic capacity of SAg constructs depends on IL-10 and TGF-β  
Anti-inflammatory cytokines like IL-10 and TGF-β play a critical role in the maintenance of 
immune tolerance. These cytokines are important in cell mediated suppression and crucial in 
the generation of regulatory FoxP3+ T cells (Powrie et al., 1996; Asseman et al., 1999; Maloy 
and Powrie, 2001; Green et al., 2003). The impact of IL-10 and TGF-β on the suppressive 
function mediated by the SAg fusion constructs in the EAE model was investigated by 
neutralization of cytokines. Monoclonal antibodies were administered intraperitoneally to 
SAg-MOG treated mice, blocking the IL-10 receptor or αTFG-β antibody. In each case, 
neutralizing antibodies were given on days 7, 9, 11 and 13 after induction of EAE. As shown 
in (Fig. 6), SAg-MOG treated animals were almost fully protected from developing EAE 
whereas concurrent abrogation of IL-10 signaling completely inhibited the protective effect 
induced by the treatment. Administration of isotype control did not impair the suppressive 
effect of the SAg construct. Protection of EAE in SAg-PLP treated SJL/J mice was also 
abolished by the neutralizing αTGF-β antibody (Fig. S6). The blockage of this specific 
signaling pathway during an autoimmune response leads to a markedly increased severity of 
the disease without any apparent signs of remission up to 30 days after EA induction. These 
results indicate an important role of suppressive cytokines like IL-10 and TGF-β in the 
induction of an active and cell mediated tolerance established following administration of the 
SAg constructs.  
3.8 S-Antigen treatment reduces antigen-specific expression of pro-
inflammatory TNF-α  
Our previous studies indicate that protection of autoimmune disease induced by repetitive 
self-epitopes is associated with the reduction of the pro-inflammatory cytokine TNF-α in 
antigen-specific T cells. Analysis of the antigen-specific production of the pro-inflammatory 
cytokine TNF-α was further investigated following SAg administration. To examine the 
antigen-specific TNF-α production by T cells from animals that received SAg fusion 
constructs, CFSE labeled OVA specific CD4+ T cells were transferred into Balb/c mice which 
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also were administered SAg-OVA, SAg-MOG or free OVA. After priming with OVA323-339 
peptide, cells recovered from lymph nodes were restimulated with the specific peptide and 
cytokine expression was analyzed on KJ1.26+ CD4+ T cells by intracellular staining of TNF-α 
(Fig. 7). Results show that treatment with unrelated SAg-MOG protein lead to a high number 
of OVA specific T cells that produce TNF-α after restimulation with OVA (45% TNF-α+ of 
total KJ1.26+ CD4+ T cells). TNF-α positive cells were reduced in mice vaccinated with free 
OVA peptide compared to control mice (29% TNF-α + of total KJ1.26+ CD4+ T cells). This 
effect was even more pronounced in mice that received SAg-OVA where a reduction of TNF-
α secretion by almost 67% was observed (15% TNF-α + of total KJ1.26+ CD4+ T cells) (Fig. 
7). No induction of IFN-γ was observed (data not shown). Furthermore, administration of SAg 
fusion proteins in B cell deficient JTH-/- mice (Fig. S7) was also associated with the down-
regulation of TNF-α production by antigen-specific T cells (Fig. S8).  
3.9 SAg fusion proteins reduce pro-inflammatory responses 
SAg fusion proteins induced suppression of Th1-mediated DTH response. Animals that 
received SAg-OVA during immunization showed to limit inflammation in comparison to 
animals that received OVA peptide, as indicated in Fig. S9. These results suggest that SAg 
fusion proteins contribute to downregulation of the inflammatory response, which is also in 
line with the observed modulatory effects of these constructs on the DTH response.  
4. Discussion 
In this study we used a novel approach that makes use of repetitive sequences derived from 
parasites as a reliable means to induce immune tolerance to specific autoantigens involved 
in disease pathology. Our previous studies have shown that repeat antigens consisting of 
linear copies of T cell epitopes are able to induce antigen-specific tolerance and suppress 
the clinical signs in various experimental autoimmune model systems (Rotzschke et al., 
1997; Falk et al., 2000b; Falk et al., 2000a; Mack et al., 2001; Stienekemeier et al., 2001; 
Piaggio et al., 2007; Puentes et al., 2013). Their suppressive effect has been correlated with 
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the induction of anergy (Falk et al., 2000a), expansion of regulatory cells (Piaggio et al., 
2007) and induction of active suppression (Puentes et al., 2013). 
The aim of this study was the determination and characterization of the suppressive capacity 
of parasite-derived repetitive sequences linked to self-epitopes. The role of parasite tandem 
repeats in host-parasite interaction and immune evasion has been correlated with an efficient 
cross-linking to receptors like MHC class molecules and B cell receptors on APCs (Vos et al., 
2000; Zinkernagel and Hengartner, 2001). There is evidence that multimeric assembly of 
repeat units of parasite ligands and host surface molecules form high-avidity complexes 
necessary for invasion (Paing and Tolia, 2014). 
Parasites have developed several mechanisms to escape immune recognition by the host 
and the remarkably high incidence of conserved repetitive structures within different species 
seems to be associated with the induction of immune suppression. Recently, growing 
evidence indicates that concomitant parasitic infections can reduce disease severity in 
different models of human autoimmune diseases (Tadokoro et al., 2004; Stevenson and 
Zavala, 2006; Walsh et al., 2009; Farias et al., 2011). For example, regulatory mechanisms 
induced during Plasmodium infection ameliorate the clinical course and immune responses 
of EAE (Farias et al., 2011) and co-infection with Trypanosoma species interferes with the 
development of EAE through a modulatory effect exerted by IL-10 that limits Th1 cells 
expansion (Tadokoro et al., 2004). Several models explaining this phenomenon have been 
proposed, including a shift from a Th1 to a Th2 T cell response (Yazdanbakhsh et al., 2001; 
Mohrs et al., 2005) as well as the induction of regulatory FoxP3+ T cells (Wilson et al., 2005).  
In the present study, the suppressive potential of repeat units in parasite proteins was 
exploited to induce targeted immunomodulation and to re-establish tolerance to self-antigens 
in an experimental autoimmune disease model. Fusion proteins consisting of repeat 
sequences derived from Plasmodium S-Antigen were covalently linked to different relevant 
single CD4+ T cell epitopes and the tolerogenic effect of the constructs was assessed in the 
EAE model. This study demonstrates that SAg fusion proteins anchored to myelin derived T 
cell epitopes are potent suppressive molecules that protect animals from developing EAE 
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when administered before disease induction or soon after the onset of the disease. 
Importantly, infiltrating T cells were barely found in the CNS cells of mice treated with SAg 
fusion proteins in comparison with untreated mice (data not shown), suggesting a recruitment 
of auto-reactive cells in peripheral tissues. Notably, neither the mixture of SAg repeat unit 
and free peptide epitope nor the parasite-repeat unit alone induced any suppression of 
disease. The antigen-specific effect of SAg fusion proteins was demonstrated by the fact that 
treatment with a fusion protein that contained an unrelated epitope did not have any effect in 
the modulation of EAE. This indicates that the physical linkage of the SAg to the CD4+ T cell 
epitope is required for the suppressive function and the effect is highly antigen-specific. A 
similar phenomenon might be occurring in Plasmodium infections as it has been reported  
that antigens containing tandem repeat sequences have T cell epitopes that are not 
immunodominant; indeed, one of the proposed functions of the repeat sequence is 
suppression of adjacent epitopes (Targett, 1992). Other preliminary data indicate that 
administration of fluorescent-labeled SAg constructs bound a distinct subset of B cells (data 
not shown) which is in line with structural features of repeats antigens that enable 
crosslinking to B cell receptors. However, SAg constructs were capable of inducing tolerance 
in B cell deficient mice, indicating that other APCs play an important role in disease 
suppression induced by these constructs. Future studies are encouraged to determine the 
role of suppressive cytokines in tolerance induced by SAg fusion proteins in mice lacking B 
cells. 
We used the transgenic DO11.10 mouse model to examine the underlying mechanisms 
involved in the tolerance induced by the constructs. Advantages of using OVA323–339 specific 
TCR transgenic DO11.10 mice include the ability to track antigen specific CD4 T cells after 
adoptive transfer. The results suggest that these fusion proteins are efficiently presented for 
the recognition of antigen-specific cells, inducing proliferation in naive transgenic T cells and 
that lymph node cells isolated from treated animals proliferate in response to peptides linked 
to fusion constructs. This indicates that SAg treatment did not lead to complete anergy or 
depletion of antigen-specific T cells.  In vivo tracking of proliferation after adoptive cell 
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transfer rather indicate that treatment led to increased frequencies of FoxP3+CD4+ 
regulatory T cells, which are known to play a central role in immune modulation (Chen et al., 
2003; Fantini et al., 2004; Ng et al., 2013; Mohammadnia-Afrouzi et al., 2015). Similarly, it 
has been described that in vitro incubation of human CD4+ T cells with a random polymer 
found in the myelin basic protein, copolymer I, can lead to FoxP3 expression, though in a 
non antigen-specific manner (Hong et al., 2005). Likewise, expansion of FoxP3 regulatory 
cells was found to be associated with protection against diabetes induced by multimerized 
epitopes (Piaggio et al., 2007). EAE experiments using FoxP3+ depleted DEREG mice (Lahl 
et al., 2007) will provide more insights into the role of regulatory T cells in SAg mediated 
suppression. 
On the other hand, neutralization of either IL-10 or TGF-β led to a complete abrogation of the 
tolerogenic effect of the SAg constructs. The blockade of TGF-β can also have a direct 
impact in the de novo induction of FoxP3+ regulatory T cells as has been previously reported 
(Horwitz et al., 2008; Shevach et al., 2008). The administration of anti-cytokine antibodies 
lead to slight increases in the clinical score of treated mice compared to control mice that did 
not receive the antibody, which can be the result of the neutralization of intrinsic protective 
cytokines. However, these differences are not as significant as the differences in the clinical 
score of mice treated with SAg fusion proteins and treated mice receiving anti-cytokine 
antibodies. In addition, in the DO11.10 transgenic model, SAg fusion proteins downregulate 
antigen-specific secretion of pro-inflammatory TNF-α, in agreement with our previous study 
showing TNF-α modulation as one of the mechanisms of oligomers induced suppression 
(Puentes et al., 2013). Future studies addressing the relevance of TNF-α in the protective 
effect of EAE induced by the fusion proteins are encouraged. Furthermore, SAg vaccination 
was also able to reduce antigen-specific DTH response, confirming its tolerogenic effect in a 
disease model where Th1 effector cell function is inhibited. DTH suppression can also be 
attributed to the action of suppressive cytokines like IL-10 that is generated during the 
exposure to SAg fusion proteins (Powrie et al., 1993). Therefore, some of the 
immunomodulatory mechanisms that may directly contribute to restore tolerance by SAg 
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constructs involve the production of suppressive cytokines, expansion of regulatory cells and 
the reduction of pro-inflammatory cytokines. 
This study suggests that SAg repeat units can function as carriers to deliver an antigen of 
interest inducing antigen-specific immunosuppression, likely by targeting APCs rendering 
them tolerogenic properties. Preliminary results indicate that SAg repeats units increase the 
bioavailability of the linked epitope-peptide compared to the free-peptide (data not shown). 
For application, SAg fusion constructs might provide some advantages over the use of 
adjuvants such as preservation of conformational structures of the peptide antigen in addition 
to their high solubility, which enable safe systemic administration.  
The inherent ability of parasite repetitive antigens represents a promising strategy to promote 
immune suppression. Thus, the use of the mechanisms involved in parasite immune evasion 
can be exploited to modulate immune responses to defined target antigens. The present 
study shows the feasibility of SAg fusion proteins as an effective approach to deliver self-
epitopes involved in the generation of autoimmune responses to induce antigen-specific 
immune suppression for the prevention and treatment of autoimmune diseases.   
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Figure 1 
 
 
 
Fig 1. Protective effect of SAg fusion constructs in the EAE model. EAE was induced in 
SJL/J mice with PLP139-151 and in C57BL/6 mice with MOG35-55. Peptides were emulsified in 
complete Freund’s adjuvant and injected subcutaneously. Pertussis toxin was injected one 
day post-immunization. 50 µg of SAg-PLP were intravenously administered to SJL/J mice (A) 
7 days prior disease induction or (B) on day 7 after EAE induction. In the MOG-EAE model, 
70 µg of SAg-MOG were intravenously injected to C57BL/6 mice (C) 7 days before disease 
induction or (D) on day 7 following EAE induction, as indicated by the arrows. As a control of 
the experiments a group of mice were left untreated. Mice were scored daily for the 
development of clinical signs of disease. Mean clinical scores of the distinct groups (n=5) 
±SEM are presented. Statistical significance between groups was determined by Mann-
Whitney U test. **P<0.01 and *P<0.05 compared with the respective control group.
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Figure 2 
 
 
 
Fig 2. Antigen-specific effect of SAg-PLP in the EAE suppression. EAE was induced in 
SJL/J mice after subcutaneous injection of PLP139-151 peptide emulsified in complete 
Freund’s adjuvant and injection of 200 ng of Pertussis toxin one day after priming. Mice were 
treated on day 7 post-immunization with SAg-PLP fusion protein or unrelated SAg-MOG 
protein. Animals were monitored daily and the average ±SEM of the clinical score of five 
mice per group was calculated. Statistical significant difference between different groups was 
observed, **P<0.01 and *P<0.05. 
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Figure 3 
 
 
 
Fig 3. Tolerogenic effect of fusion constructs requires physical linkage. EAE was 
induced in SJL/J mice with 50 µg of PLP139-151 in complete adjuvant containing 
Mycobacterium tuberculosis. Mice were treated intravenously on day 7 post-immunization 
with 50 µg of SAg-PLP or with equimolar amounts of free SAg together with free PLP139-151 
peptide. Control animals were left untreated. Animals were scored daily for the development 
of clinical signs of the disease and the average ±SEM of five mice per group was calculated. 
Statistical significance between mice treated with SAg-PLP fusion protein and mice receiving 
a mixture of the S-Ag repeat unit and free PLP peptide was determined by Mann-Whitney U 
test. **P<0.01 and *P<0.05.  
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Figure 4 
 
 
 
Fig 4. In vivo antigen-specific CD4+ T cell response after SAg-OVA administration. 
CD4+ T cells specific for OVA323-339 were isolated from DO11.10 mice and labeled with 5µM 
CFSE. 3x106 CD4+ T cell were adoptively transferred intravenously into sex-matched 
recipient Balb/c mice. One day after, mice were given titrated amounts of free OVA323-339 or 
SAg-OVA (equimolar amounts, based on OVA-peptide amount). Mice were sacrificed on day 
6 and lymph node cells were isolated. Antigen-specific proliferation was determined by 
analyzing the CFSE profile gated on CD4+ KJ1.26+ T cells by flow cytometry. A 
representative plot of 3 independent experiments is shown. 
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Figure 5 
 
 
 
Fig 5. Increased frequency of FoxP3+ regulatory CD4+ T cells following the treatment 
with SAg constructs. To investigate the impact of FoxP3+ Tregs on the tolerogenic function 
of SAg constructs in vivo, 3x106 DO11.10 CD4+ CFSE labeled T cells were intravenously 
transferred into Balb/c mice. One day later, mice received intravenously 5 µg of free OVA323-
339, 60 µg of SAg-OVA (equimolar amounts, based on OVA-peptide amount) or 60 µg of 
SAg-MOG as control. Lymph node cells were isolated on day 6. (A) Frequency of Treg cells 
were determined by intracellular staining of FoxP3 in proliferating OVA-specific cells and in 
(B) CD25+ cells in gated KJ1.26+ CD4+ T cells by FACS. Numbers indicate frequencies 
FoxP3+ Treg cells. Representative plots of 2 independent experiments are shown. 
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Figure 6 
 
 
 
Fig 6. Impact of in vivo neutralization of suppressive cytokines on the protective effect 
induced by SAg fusion proteins. EAE was induced in C57BL/6 mice with MOG35-55 peptide 
and received 70 µg of SAg-MOG administered intravenously on day 7 after priming or were 
left untreated. To neutralize IL-10, animals received 0,5 mg of αIL-10R antibody (anti-IL-10 
receptor) or isotype control IgG1 antibody. Antibodies were administered intraperitoneally on 
days 7, 9, 11 and 13 as indicated by the arrows. Animals were scored daily for the 
development of clinical signs of disease. Mean clinical scores ±SEM are presented. 
Statistical significance between treated mice receiving or not receiving neutralizing αIL-10R 
antibody was determined by Mann-Whitney U test. **P<0.01 and *P<0.05. 
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Figure 7 
 
 
Fig 7. Antigen-specific suppression of pro-inflammatory TNF-α following treatment 
with SAg constructs. To investigate the impact of tolerogenic constructs on antigen-specific 
CD4+ effector T cell responses in vivo, 3x106 DO11.10 CD4+ T cells were adoptively 
transferred intravenously into Balb/c mice. Mice received 5 µg of free OVA323-339, 60 µg of 
SAg-OVA (equimolar amounts, based on OVA-peptide amount) or 60 µg of SAg-MOG as 
control one day after transfer. Mice were primed on day 7 by subcutaneous administration of 
5 µg OVA323-339 peptide in CFA. Mice were sacrificed 6 days later and lymph node cells were 
collected and restimulated with 10 µg/ml OVA peptide and control peptide for 6 hours. 
Antigen-specific cytokine expression was analyzed on KJ1.26+ CD4+ T cells by intracellular 
staining of TNF-α. The plots show the frequencies of TNF-α+ cells analyzed on gated CD4+ 
KJ1.26+ T cells. 
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Figure S1 
 
Fig S1. Generation of parasite-derived fusion proteins. (A) Schematic diagram of fusion 
proteins. Parasite repetitive structures were fused through a linker to CD4+ T cell antigens 
and expressed in E.coli. Fusion proteins containing repetitive sequences of the S-antigen 
(SAg) of P. falciparum were designed: 24 repeats of a 8-mer unit derived from the NF7 
isolate (A(L/R)KSDEAE) were linked to the N-terminus of the respective CD4+ T cell 
epitopes: MOG38-51 (SAg-MOG38-51), PLP139-151 (C140S) (SAg-PLP139-151) and OVA323-339 
(SAg-OVA323-339). Since the natural units contained either L or R in their repeats, building 
blocks with alternating amino acids were used in tandem repeats. (B) Analysis of the 
expression of epitope fusion-constructs containing S-Antigen repeats fused to CD4 T cell 
epitopes in E. coli. Lane 1: SAg 12-mer (22 KDa); lane 2: SAg 12-mer MOG38-51 S3 (24Kda); 
lane 3: SAg 12-mer PLP139-151 S3 (24 KDa) and lane M: molecular weight markers. The 
weights calculated from the DNA sequence are lower compared to those estimated from the 
SDS gel due to abnormal SDS binding (SAg sequence is 38% ASP and GLU) (Matagne et 
al.,1991).
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Fig S2. Therapeutic effect of SAg fusion proteins. SJL/J mice (n=8) were individually 
treated once the first clinical signs of EAE appeared. 50 g of SAg-PLP fusion protein was 
given intravenously to diseased mice. Administration of fusion protein inhibits the evolution of 
EAE. The curve shows the mean ±SEM daily clinical score. Statistical significance between 
groups was determined by Mann-Whitney U test. **P<0.01 and *P<0.05. 
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Fig S3. Antigen-specific EAE protection after vaccination with SAg-PLP fusion 
proteins. EAE was induced in SJL/J mice using 50 g of the encephalitogenic PLP139-151 
peptide in CFA. The following day, animals received 200 ng of Pertussis toxin. Mice were 
vaccinated 7 days prior disease induction with 50 g of SAg-PLP139-151 or unrelated SAg-
OVA323-339 fusion proteins. Mice were monitored daily and the mean clinical score of five 
mice per group was plotted. One representative experiment of two performed is shown. 
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Fig S4. SAg repeat unit alone does not induce protection in the MOG-EAE model. EAE 
was induced in C57BL/6 mice by priming with 50 µg of MOG35-55 peptide and injection of 500 
ng of Pertussis toxin one day after priming. Mice were vaccinated 7 days before disease 
induction with 70 µg of SAg-MOG fusion protein or SAg only. Mice were monitored daily and 
the average ±SEM of the clinical score of five mice per group was calculated.  
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Figure S5 
 
 
 
Fig S5. T cell proliferation induced by SAg fusion protein. To compare the proliferative 
capacity of free peptide and SAg fusion constructs in vitro, [3H]Thymidine proliferation assay 
was performed. Lymph node cells were harvested from DO11.10 mice and 5x105 cells were 
incubated for 96 hours with titrated amounts of SAg-OVA, free OVA323-339 and MOG38-51 as 
negative control. [3H]Thymidine was added after 72 hours. Counts per minute (cpm) mean 
values and standard deviation of triplicates are shown.  
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Fig S6. Impact of in vivo neutralization of TGF-β on the protective effect induced by 
SAg fusion proteins. EAE was induced in SJL/J mice with PLP139-151 peptide. On day 7 
after EAE induction, mice received intravenously 50 µg of SAg-PLP or in combination with 
0.5 mg of αTGF-β antibody. Control groups were left untreated with or without αTGF-β 
antibody treatment. Neutralizing antibodies were administered intraperitoneally on days 7, 9 
and 11. Animals were scored daily for the development of clinical signs of the disease. Mean 
clinical score from the groups (n=5) are presented.  
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Figure S7 
 
 
 
Fig S7. Suppressive capacity of SAg constructs is independent of B cells. EAE was 
induced in JHT+/- and JHT-/- mice after subcutaneous immunization with MOG35-55 peptide 
emulsified in adjuvant containing Mycobacterium tuberculosis and injection of Pertussis toxin. 
Mice were treated with SAg-MOG fusion protein and monitored daily. Averages of the clinical 
scores were calculated. The plot shows that SAg constructs can also induce tolerogenic 
effect in B cell deficient JHT-/- mice. 
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Fig S8. Antigen-specific suppression of pro-inflammatory TNF-α following treatment 
with SAg fusion proteins in B cell deficient mice. To measure the production of TNF-α in 
JHT-/- mice, OTII (OVA323-339 specific) cells labeled with CFSE were transferred into OVA323-
339 primed JHT+/- and JHT-/- mice and treated with SAg-OVA.  Lymph node cells were isolated 
from treated and untreated mice and activated for 6 hours with OVA323-339 peptide and α-
CD28. Cytokine secretion was blocked by the addition of Brefeldin A for the last 4 hours of 
stimulation. Cells were stained for surface CD4 followed by intracellular staining with αTNF-
α. For analysis of TNF-α in antigen-specific activated T cells; combined intracellular α-CD154 
staining was performed. The frequency of CD154+TNF-α+ double positive in OTII CD4+ T 
cells was determined and analyzed by FACSDivaTM software (BD Bioscience). 
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Fig S9. Suppressive capacity of SAg-OVA in a DTH model. OVA323-339 specific T cells 
were isolated from DO11.10 mice and 3x106 CD4+ T cell were adoptively transferred 
intravenously into Balb/c mice. One day later, mice were tolerized by intravenous 
administration of 5µg free OVA323-339 or 60µg SAg-OVA (equimolar amounts, based on OVA-
peptide amount). DTH reaction was induced on day 7 by adoptive transfer of OVA-specific 
cells that were cultured for 6 days under Th1 polarizing conditions. One day later mice were 
immunized into the footpad by intradermal injection of 250 ng OVA323-339 in IFA or PBS/ IFA. 
DTH reaction was measured 8 days post immunization by determining footpad swelling 
compared to days zero. 
 
